Simulations Plus (NASDAQ:SLP) Hits New 12-Month Low at $31.72

Shares of Simulations Plus, Inc. (NASDAQ:SLP) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $31.72 and last traded at $31.85, with a volume of 2090 shares. The stock had previously closed at $31.89.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on SLP shares. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research note on Thursday, September 12th. KeyCorp started coverage on Simulations Plus in a research note on Monday, July 29th. They set an “overweight” rating and a $47.00 price target for the company. Craig Hallum reaffirmed a “buy” rating and set a $56.00 price target on shares of Simulations Plus in a research note on Wednesday, July 3rd. JMP Securities started coverage on Simulations Plus in a research note on Tuesday, July 16th. They set a “market perform” rating for the company. Finally, Oppenheimer lifted their price target on Simulations Plus from $55.00 to $65.00 and gave the stock an “outperform” rating in a research note on Thursday, June 13th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $56.00.

Simulations Plus Trading Down 0.1 %

The company has a market cap of $637.25 million, a PE ratio of 66.44 and a beta of 0.70. The business has a fifty day moving average of $37.36 and a 200-day moving average of $42.83.

Simulations Plus (NASDAQ:SLP) last posted its earnings results on Tuesday, July 2nd. The technology company reported $0.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.04. Simulations Plus had a return on equity of 7.80% and a net margin of 14.36%. The firm had revenue of $18.54 million for the quarter, compared to the consensus estimate of $17.92 million. During the same quarter in the prior year, the business earned $0.20 EPS. The business’s revenue for the quarter was up 14.2% on a year-over-year basis. As a group, research analysts predict that Simulations Plus, Inc. will post 0.51 EPS for the current year.

Simulations Plus Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 5th. Stockholders of record on Monday, July 29th were given a $0.06 dividend. The ex-dividend date was Monday, July 29th. This represents a $0.24 dividend on an annualized basis and a dividend yield of 0.75%. Simulations Plus’s dividend payout ratio is currently 50.00%.

Insider Transactions at Simulations Plus

In other news, Director Daniel L. Weiner sold 750 shares of the business’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $49.32, for a total value of $36,990.00. Following the sale, the director now directly owns 7,009 shares of the company’s stock, valued at approximately $345,683.88. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $35.18, for a total transaction of $703,600.00. Following the transaction, the director now owns 3,501,592 shares in the company, valued at approximately $123,186,006.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Daniel L. Weiner sold 750 shares of the firm’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $49.32, for a total value of $36,990.00. Following the completion of the transaction, the director now directly owns 7,009 shares in the company, valued at $345,683.88. The disclosure for this sale can be found here. Insiders have sold a total of 60,750 shares of company stock valued at $2,467,390 in the last ninety days. 20.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Azzad Asset Management Inc. ADV grew its position in shares of Simulations Plus by 3.6% during the second quarter. Azzad Asset Management Inc. ADV now owns 8,007 shares of the technology company’s stock worth $389,000 after purchasing an additional 280 shares in the last quarter. InTrack Investment Management Inc lifted its position in shares of Simulations Plus by 1.1% in the second quarter. InTrack Investment Management Inc now owns 31,665 shares of the technology company’s stock worth $1,540,000 after buying an additional 330 shares in the last quarter. Chatham Capital Group Inc. grew its holdings in Simulations Plus by 1.3% during the 2nd quarter. Chatham Capital Group Inc. now owns 34,554 shares of the technology company’s stock valued at $1,680,000 after buying an additional 450 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Simulations Plus by 7.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 6,391 shares of the technology company’s stock worth $311,000 after acquiring an additional 456 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Simulations Plus by 5.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,048 shares of the technology company’s stock worth $414,000 after acquiring an additional 562 shares in the last quarter. 78.08% of the stock is currently owned by institutional investors.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.